- Home
- SNY vs BMY Comparison
SNY vs BMY Comparison
Compare SNY & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNY | BMY |
|---|---|---|
| Founded | 1994 | 1887 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.4B | 110.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SNY | BMY |
|---|---|---|
| Price | $48.43 | $56.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $61.50 | $56.31 |
| AVG Volume (30 Days) | 2.4M | ★ 15.3M |
| Earning Date | 01-29-2026 | 02-05-2026 |
| Dividend Yield | 3.32% | ★ 4.63% |
| EPS Growth | ★ 105.93 | N/A |
| EPS | ★ 8.67 | 2.97 |
| Revenue | ★ $53,890,648,839.00 | $48,034,000,000.00 |
| Revenue This Year | $1.73 | $0.27 |
| Revenue Next Year | $6.49 | N/A |
| P/E Ratio | ★ $5.55 | $18.32 |
| Revenue Growth | N/A | ★ 1.26 |
| 52 Week Low | $44.62 | $42.52 |
| 52 Week High | $60.12 | $63.33 |
Technical Indicators
Market Signals| Indicator | SNY | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 70.91 |
| Support Level | $47.17 | $52.06 |
| Resistance Level | $48.95 | $55.04 |
| Average True Range (ATR) | 0.54 | 0.93 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 75.77 | 94.66 |
Price Performance
Historical ComparisonAbout SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.